• Citer

Corrigendum: Cemiplimab for advanced cutaneous squamous cell carcinoma in kidney transplant recipients (Néphrologie & Thérapeutique, (2022), 18, 5, (372), 10.1016/j.nephro.2022.07.395)

par Van Meerhaeghe, Tess ;Baurain, Jean-Francois;Bechter, Oliver;Orte Cano, Carmen ;Del Marmol, Véronique ;Devresse, Arnaud;Doubel, Peter;Hanssens, Marianne;Hellemans, Rachel;Lienard, Danielle ;Rutten, Annemie;Sprangers, Ben;Le Moine, Alain ;Aspeslagh, Sandrine
Référence Nephrology frontier, 2, 1129134
Publication Publié, 2022

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Résumé :

In the published article, there was a mistake in the Funding statement. The following statement should be removed: “TM declares that this study received funding from Sanofi and Bristol Myers Squibb. The funders were not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication”. The correct statement appears below.